Cardioxyl Pharmaceuticals
ClosedTowson, United States · Founded 2005 · $42.5M raised
- Headquarters
- Towson, Maryland
- Employees
- 11–50
- Founded
- 2005
- Business Model
- B2B
- Website
- cardioxyl.com
- Total Funding
- $42.5M
- Last Round
- $14.5M Series ANov 2012
- Rounds
- 2
About
Cardioxyl Pharmaceuticals was a private biotechnology company focused on the discovery and development of novel therapeutic agents for cardiovascular disease, particularly heart failure. Its lead asset, CXL-1427, was a nitroxyl (HNO)-releasing prodrug with a novel mechanism of action that advanced to Phase 2 clinical trials for acute decompensated heart failure. Bristol-Myers Squibb acquired Cardioxyl in November 2015 for $300 million upfront and up to $1.78 billion in milestone payments.
Summary
Cardioxyl Pharmaceuticals is a Biotech company based in Towson, United States, founded in 2005. It has raised $42.5M in total across 2 rounds, most recently a $14.5M Series A round in Nov 2012. Investors include New Enterprise Associates, The Aurora Funds and Bristol Myers Squibb.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2015
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...